Full Press Release Details
J.P. Morgan 39 th Annual Healthcare Conference January 2021 Forward - Looking Statements Certain information contained in this presentation includes "forward - looking statements", within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our clinical trials and regulatory submissions. We may, in some cases use terms such as "predicts," "believes," "potential," "con tin ue," "anticipates," "estimates," "expects," "plans," "intends," "may," "could," "might," "likely," "will," "should" or other words th at convey uncertainty of the future events or outcomes to identify these forward - looking statements. Our forward - looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward - looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward - looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or ot her studies and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Quarterl y Report on Form 10 - Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward - looking statements. You are cautioned not to place undue reliance on these forward - looking statements, which are made only as of the date of this presentation. We undertake no obligation to publicly update such forwa rd - looking statements to reflect subsequent events or circumstances. 2021 Aprea Therapeutics. All Rights Reserved 2 Aprea Therapeutics The global leader in p53 - targeted therapies for the treatment of cancer Proof - of - concept and proof - of - principle demonstration of mutant p53 reactivation Presentation Agenda Update on Phase 3 MDS Clinical Study Development Pipeline 1L AML Post - transplant maintenance in MDS/AML CLL / MCL Advanced solid tumors Financial and Operational Highlights 2021 Milestones 2021 Aprea Therapeutics. All Rights Reserved 3 p53: The "Guardian of the Genome" 2021 Aprea Therapeutics. All Rights Reserved 4 p 53 tumor suppressor The nexus and regulator of key anti - cancer network of signals Triggers cell cycle arrest and apoptosis in response to DNA damage and other cellular stresses The most frequently mutated gene in human cancers Mutations in the TP53 gene occur in approximately 50% of tumors p53 mutations destabilize the protein and lead to protein misfolding Mutations are associated with very poor prognosis TP53 mutations compromise tumor suppressive function and can promote tumor growth and metastasis Reactivation of Mutant p53 Across Mutation Types p53 protein destabilization is a general and direct consequence of mutation Eprenetapopt MoA is agnostic to specific p53 mutation, capitalizes on principles of protein folding & stability Activity observed in nearly 100 different p53 mutations in preclinical studies across hot spots and other mutations Clinical responses recorded in patients spanning more than 80 unique p53 mutations across hot spots and other mutations 2021 Aprea Therapeutics. All Rights Reserved 5 6723 misfolded mutant p53 cell cycle arrest apoptosis + eprenetapopt reactivated p53 with wild - type structure p53 reactivation Clinical Development 2021 Aprea Therapeutics. All Rights Reserved 6 Molecule Indication Preclinical Phase 1 Phase 2 Phase 3 Eprenetapopt (APR - 246) 1L TP53 Mutant MDS 1 1L TP53 Mutant MDS and AML (U.S. study) 2 1L TP53 Mutant MDS and AML (French study) 2 TP53 Mutant MDS and AML Post - Transplant Maintenance 1L and R/R TP53 Mutant AML R/R TP53 Mutant CLL and MCL Advanced Gastric, Bladder, NSCLC APR - 548 1L and R/R TP53 Mutant MDS Execution on Clinical Develop